Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Longitudinal Changes in Diabetic Retinopathy Severity: Learnings from PANORAMA.
Wykoff CC, Do DV, Clark WL, Boyer DS, Dhoot DS, Marcus DM, Vitti R, Berliner AJ, Reed K, Cheng Y, Moini H, Brown DM. Wykoff CC, et al. Among authors: do dv. Ophthalmol Retina. 2025 Jan;9(1):91-94. doi: 10.1016/j.oret.2024.10.007. Epub 2024 Oct 16. Ophthalmol Retina. 2025. PMID: 39424059 Free article. No abstract available.
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Rao R, Cheng Y, Sun W, Voronca D, Bhore R, Schmidt-Ott U, Schmelter T, Schulze A, Zhang X, Hirshberg B, Yancopoulos GD, Sivaprasad S; PHOTON Investigators. Brown DM, et al. Among authors: do dv. Lancet. 2024 Mar 23;403(10432):1153-1163. doi: 10.1016/S0140-6736(23)02577-1. Epub 2024 Mar 7. Lancet. 2024. PMID: 38461843 Clinical Trial.
Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2.
Pauleikhoff D, Bonelli R, Dubis AM, Gunnemann F, Rothaus K, Charbel Issa P, Heeren TF, Peto T, Clemons TE, Chew EY, Bird AC, Sallo FB; MacTel Study Group. Pauleikhoff D, et al. Acta Ophthalmol. 2019 Nov;97(7):e998-e1005. doi: 10.1111/aos.14110. Epub 2019 Apr 9. Acta Ophthalmol. 2019. PMID: 30968592 Free PMC article.
Methanol Activation: Strategies for Utilization of Methanol as C1 Building Block in Sustainable Organic Synthesis.
Tran HV, Dang TT, Nguyen NH, Tran HT, Nguyen DT, Do DV, Le TS, Ngo TH, Late YKE, Amaniampong PN, Fletcher E, Hung TQ, Cheng Y, Nguyen TK, Tran TS, Zhang J, An H, Nguyen NT, Trinh QT. Tran HV, et al. Among authors: do dv. ChemSusChem. 2024 Nov 18:e202401974. doi: 10.1002/cssc.202401974. Online ahead of print. ChemSusChem. 2024. PMID: 39555972 Review.
FeBr3-catalysed synthesis of 3-aroylimidazo[1,2-a]pyridine and 3,3'-(arylmethylene)bis(2-phenylimidazo[1,2-a]pyridines) derivatives from 2-arylimidazo[1,2-a]pyridines and aromatic aldehydes: an investigation about mechanistic insights.
Hung TQ, Phuc BV, Nguyen MP, Tran TL, Do DV, Nguyen HT, Nguyen VT, Nguyen H, Dang TT. Hung TQ, et al. Among authors: do dv. RSC Adv. 2024 Sep 18;14(40):29535-29541. doi: 10.1039/d4ra05198j. eCollection 2024 Sep 12. RSC Adv. 2024. PMID: 39297035 Free PMC article.
Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI).
Sharma A, Kaiser PK, Tadayoni R, Holz FG, Nicholson L, Vazquez-Alfageme C, Sivaprasad S, Wakabayashi T, Woo SJ, Sarraf D, Kumar N, Parachuri N, Regillo CD, Rezaei KA, Khanani AM, Bandello F, Shanamugam M, Verma L, Dogra MR, Ns M, Agarwal M, Loewenstein A, Kuppermann BD; International Retina Biosimilar Study Group (Inter BIOS Group). Sharma A, et al. Eye (Lond). 2024 Dec;38(17):3392-3395. doi: 10.1038/s41433-024-03284-x. Epub 2024 Aug 26. Eye (Lond). 2024. PMID: 39187656 No abstract available.
300 results